AG-024322 is primarily investigated for its potential applications in the field of oncology. It functions as a cyclin-dependent kinase (CDK) inhibitor, targeting specific CDKs involved in cell cycle regulation. By inhibiting these kinases, AG-024322 aims to halt the proliferation of cancer cells, particularly in tumors where uncontrolled cell division is driven by CDK activity. Its development is focused on exploring its efficacy in treating various cancers, including solid tumors and hematologic malignancies. Research is ongoing to determine its therapeutic potential, optimal dosing, and safety profile in clinical settings.